High expression of PD-L1 is associated with shorter survival and resistance to targeted therapies in patients with EGFR-mutant lung adenocarcinoma, according to a new study. While PD-L1 expression has been shown to be associated with response to immunotherapy, previous reports have yielded conflicting results on whether it is also predictive for EGFR tyrosine kinase inhibitor ...
Lung cancer
PD-L1 points to poor outcomes in EGFR lung cancer
By Dave Levitan
22 Mar 2021